Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) COO Marianna Mancini sold 18,026 shares of the company’s stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $57.13, for a total transaction of $1,029,825.38. Following the sale, the chief operating officer now directly owns 362,149 shares of the company’s stock, valued at approximately $20,689,572.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Viking Therapeutics Price Performance
Viking Therapeutics stock opened at $53.05 on Friday. The business has a 50 day moving average of $54.99 and a 200-day moving average of $57.43. Viking Therapeutics, Inc. has a 1 year low of $8.28 and a 1 year high of $99.41. The company has a market capitalization of $5.85 billion, a P/E ratio of -57.04 and a beta of 1.03.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last released its earnings results on Wednesday, July 24th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06. During the same quarter last year, the company posted ($0.19) EPS. Equities analysts anticipate that Viking Therapeutics, Inc. will post -0.99 EPS for the current year.
Wall Street Analysts Forecast Growth
Hedge Funds Weigh In On Viking Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Massmutual Trust Co. FSB ADV bought a new position in shares of Viking Therapeutics during the 1st quarter worth approximately $25,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Viking Therapeutics during the 2nd quarter worth approximately $27,000. Lindbrook Capital LLC boosted its holdings in shares of Viking Therapeutics by 370.7% during the 1st quarter. Lindbrook Capital LLC now owns 353 shares of the biotechnology company’s stock worth $29,000 after buying an additional 278 shares in the last quarter. Wetzel Investment Advisors Inc. bought a new position in shares of Viking Therapeutics during the 4th quarter worth approximately $37,000. Finally, LifeSteps Financial Inc. bought a new position in shares of Viking Therapeutics during the 1st quarter worth approximately $37,000. 76.03% of the stock is currently owned by institutional investors.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Articles
- Five stocks we like better than Viking Therapeutics
- What is the Euro STOXX 50 Index?
- Should You Invest in Bitcoin? Pros and Cons
- How to Invest in Small Cap Stocks
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- How to Evaluate a Stock Before Buying
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.